العربية
Source-based drug explainer

What is Foundayo?

Foundayo is the brand name for orforglipron, an oral GLP-1 receptor agonist tablet approved by the U.S. FDA for chronic weight management in eligible adults when used with reduced-calorie diet and increased physical activity.

Read the overview → Check sources

Independent informational website. Not affiliated with Eli Lilly, FDA, Drugs.com, WebMD, or Form Health.

Quick snapshot

Generic nameorforglipron
Drug classGLP-1 receptor agonist
FormOnce-daily oral tablet
Use described by FDAChronic weight management in eligible adults

Clear overview

Foundayo is not an injection. Public drug references describe it as a tablet form of orforglipron, a small-molecule GLP-1 receptor agonist. GLP-1 medicines are associated with appetite and weight-management pathways.

The FDA approval announcement states that Foundayo is used together with reduced-calorie diet and increased physical activity to reduce excess body weight and help maintain weight reduction long term in adults with obesity, or adults with overweight and at least one weight-related comorbidity.

This page is for general education only and does not provide personal medical advice.

Important guides

Foundayo vs Ozempic: what is the main difference?

A simple comparison of format, drug class, and the reason people are talking about oral GLP-1 tablets.

Read section

Foundayo side effects and warnings explained

A source-based summary of commonly listed side effects and serious warnings without giving personal treatment advice.

Read section

When was Foundayo approved?

A timeline-style guide summarizing the FDA announcement, approval date, and what was publicly stated.

Read section

Foundayo dosage: what public sources say

A careful overview of listed tablet strengths and titration context from public references.

Read section

Safety topics mentioned by sources

Public sources mention warnings and precautions including pancreatitis, severe gastrointestinal reactions, kidney injury related to volume depletion, hypoglycemia, hypersensitivity, diabetic retinopathy in people with type 2 diabetes, gallbladder disease, aspiration risk during anesthesia or deep sedation, and a boxed warning related to thyroid C-cell tumors.

Key facts from public sources

  1. FDA approval date: April 1, 2026.
  2. FDA granted approval to Eli Lilly and Company.
  3. Drugs.com lists tablet strengths including 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, and 17.2 mg.
  4. The FDA announcement lists common side effects such as nausea, constipation, diarrhea, vomiting, dyspepsia, stomach pain, headache, fatigue, reflux, gas, and hair loss.

Frequently asked questions

Is Foundayo the same as orforglipron?

Foundayo is the brand name, while orforglipron is the generic name listed by public drug references.

Is Foundayo a pill or injection?

Public sources describe Foundayo as an oral tablet taken once daily.

Is this website medical advice?

No. This website is a neutral information guide and does not tell anyone whether they should use Foundayo.

Where should information be verified?

Important details should be verified through official labeling, the FDA, Drugs.com, WebMD, the manufacturer, and a licensed clinician.

References used

FDAwww.fda.gov Drugs.comwww.drugs.com WebMDwww.webmd.com Form Healthwww.formhealth.co